Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2325 July 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Niraparib		
Initial application Applications Applications from any relevant practitioner. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate) Patient has advanced high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer and		
Patient has received at least one line** of treatment with platinum-based chemotherapy		
Patient has experienced a partial or complete response to the preceding treatment with platinum-based chemotherapy		
and Patient has not previously received funded treatment with a PARP inhibitor and		
Treatment will be commenced within 12 weeks of the patient's last dose of the preceding platinum-based regimen or		
Patient commenced treatment with niraparib prior to 1 May 2024		
and Treatment to be administered as maintenance treatment and		
Treatment not to be administered in combination with other chemotherapy		
Renewal		
Current approval Number (if known):		
Applications from any relevant practitioner. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate)		
No evidence of progressive diseas	е	
Treatment to be administered as maintenance treatment		
and Treatment not to be administered in combination with other chemotherapy and		
Treatment with niraparib to cease after a total duration of 36 months from commencement		
Treatment with niraparib is b	eing used in the second-line or later maintenance se	tting

I confirm the above details are correct and that in signing this form I understand I may be audited.

Note: * "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.
**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments